BIOTRONIK landed FDA approval for its*Iperia ProMRI HF-T cardiac resynchronization therapy defibrillator (CRT-D) which permits safe full-body MRI scans (up to 1.5 Tesla) given certain conditions. The device features wireless daily transmission of cardiac activity, including any arrhythmias and cardiac failure events, that can be reviewed by the patient’s cardiologist on a regular basis. Additionally, closed loop stimulation capability automatically changes the heart rate depending on the body’s demands from the heart.
Some features according to*the product page:
MultiSelect LV offers electronic repositioning options to select the optimal stimulation site, manage phrenic nerve stimulation and achieve excellent pacing threshold to improve CRT therapy.
BIOTRONK CRT-Ds provide up to 7.5 years of longevity to reduce the likelihood of*device replacement and the risks associated with it.
BIOTRONIK CRT-Ds provide automatic, daily implant-based telemonitoring, leading*to a > 50% reduction in mortality for heart failure patients, as proven by the
IN-TIME trial.
BIOTRONIK CRT-Ds with Home Monitoring reduce the number of patients*receiving inappropriate shocks by 52% as proven by the ECOST trial.
05-04-2016, 03:17 AM
BIOTRONIK’s Iperia ProMRI HF-T CRT-D Approved in U.S.
العرض العادي
